PIP
MYGN icon

Palisades Investment Partners’s Myriad Genetics MYGN Stock Holding History

Palisades Investment Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-48,100
Closed -$1.13M – 79
2013
Q3 		$1.13M Hold
48,100
– – 1.06% 41
2013
Q2 		$1.29M Buy
+48,100
New +$1.39M 1.28% 32

Other funds holding MYGN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LCG
Luxor Capital Group New York $1.43B AUM 30.88% 1-Year Est. Return
MCM
Munder Capital Management Birmingham, Michigan $13.4B AUM 18.35% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.28B AUM 23.15% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Palisades Investment Partners's MYGN Position: Q4 2013 in Review

Palisades Investment Partners sold out of Myriad Genetics (MYGN) in Q4 2013, closing a stake of 48,100 shares — an estimated $1.13M sold.

Palisades Investment Partners first reported a position in MYGN in Q2 2013 and held it in 2 quarters. The position peaked at $1.29M in Q2 2013. 270 funds tracked by Wall St. Rank hold MYGN as of Q4 2013.

  • Palisades Investment Partners reported no remaining Myriad Genetics position as of Q4 2013 after selling out during the quarter.
  • Palisades Investment Partners sold 48,100 Myriad Genetics shares in Q4 2013, an estimated $1.13M.
  • Palisades Investment Partners first reported a position in Myriad Genetics in Q2 2013 and held it in 2 quarters.
  • Palisades Investment Partners's Myriad Genetics position peaked at $1.29M in Q2 2013.
  • 270 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2013.

Based on Palisades Investment Partners's 13F filing for Q4 2013, filed 16 Jan 2014.